Cabozantinib for liver cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is testing a pill called cabozantinib for people with advanced liver cancer (HCC) that has grown despite prior treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin). The goal is to see if cabozantinib can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hepatocellular carcinoma (HCC, a type of liver cancer).
- You must have already been treated with atezolizumab and bevacizumab, and your cancer got worse after that treatment.
- You should be in fairly good health (able to take care of yourself, ECOG score 0 or 1).
- Your liver function must be adequate (Child-Pugh score A or B7).
- You cannot have had more than one prior systemic treatment for advanced liver cancer, or have received cabozantinib before.
- You must not have uncontrolled bleeding, brain metastases, or need blood thinners at full doses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
This trial tests the drug cabozantinib for people with advanced liver cancer (HCC) that has worsened after the first treatment with certain immune therapy combinations. It aims to see if cabozantinib can help control the cancer.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.